<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

The Cancer Letter

Beta Blockers Negate Harmful Recurrence Risks of ACE Inhibitors

Study Validates “PEM” Scans As Biopsy Guidance Method

Prostatectomy Lowers Death Risk Compared to Watchful Waiting

Postponed Surgery For Low-Grade Prostate Cancer Adds No Risk

Acupuncture Can Relieve Side Effects of Hormone Treatment

Selumetinib Displays Positive Results, 60% with Stable Disease

National Health Organizations Warn of Risks in Indoor Tanning

Clinical Trials Approved By NCI CTEP Last Month

SWOG Launching New Study Based on Recurrence Test Scores

Centocor Withdraws Yondelis After FDA Calls for New Study